

Protex Mobility, Inc.

One West Las Olas Blvd., Ste 500
Fort Lauderdale, FL. 33301

+27 79 107 0886

www.protxtm.com

exportintl@aol.com

SIC 2833

Quarterly Report

For the period ending March 31, 2026 (the “Reporting Period”)

Outstanding Shares

The number of shares outstanding of our Common Stock was:

8,791,221,631 as of March 31, 2026 *(Current Reporting Period Date or More Recent Date)*

8,791,221,631 as of December 31, 2025 *(Most Recent Completed Fiscal Year End)*

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control⁴ of the company has occurred during this reporting period:

Yes: No:

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

Protex Mobility- December 2010 - present
EchoMetrix- May, 2009- December, 2010
SearchHelp, Inc.- September, 2001 -May, 2009

Current State and Date of Incorporation or Registration: Delaware, 12/21/2010
Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:
N/A

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On June 3, 2022, the Company acquired 100% of the capital stock of RSAMMD Acquisitions LLC, a Delaware company, in exchange for 100,000 shares of Series D Preferred stock and 50,000 shares of Series A Preferred stock. Combined, these shares entitle the shareholders of RSAMMD to 85% of the votes on all shareholder matters with conversion rights equal to the number of votes. Mr.Dylon Du Plooy and Dr. Ahmed Jamalooden are the principals of this entity and are the beneficial owners of the Protex controlling stock.

Address of the issuer's principal executive office:

⁴ "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

One West Las Olas Blvd., Ste 500 Fort
Lauderdale, FL. 33301

Address of the issuer's principal place of business:

Check if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: Yes: If Yes, provide additional details below:

2) Security Information

Transfer Agent

Name: Clear Trust, LLC
Phone: 813-235-4490
Email: inbox@cleartrusttransfer.com
Address: 16540 Pointe Village Dr.
Suite 205 Lutz, Fl
33558

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	<u>TXTM</u>	
Exact title and class of securities outstanding:	<u>Common Stock</u>	
CUSIP:	<u>74371E204</u>	
Par or stated value:	<u>\$0.00001</u>	
Total shares authorized:	<u>10,000,000,000</u>	<u>as of date: March 31, 2026</u>
Total shares outstanding:	<u>8,791,221,631</u>	<u>as of date: March 31, 2026</u>
Total number of shareholders of record:	<u>163</u>	<u>as of date: March 31, 2026</u>

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security:	<u>Series A Convertible Preferred Stock</u>	
CUSIP (if applicable):	n/a	
Par or stated value:	<u>\$0.001</u>	
Total shares authorized:	<u>100,000</u>	<u>as of date: March 31, 2026</u>
Total shares outstanding (if applicable):	<u>50,000</u>	<u>as of date: March 31, 2026</u>
Total number of shareholders of record (if applicable):	<u>2</u>	<u>as of date: March 31, 2026</u>

Exact title and class of the security:	<u>Series B Preferred Stock</u>	
CUSIP (if applicable):	N/A	
Par or stated value:	<u>\$0.0001</u>	
Total shares authorized:	<u>1,000,000</u>	<u>as of date: March 31, 2026</u>
Total shares outstanding (if applicable):	<u>0</u>	<u>as of date: March 31, 2026</u>
Total number of shareholders of record (if applicable):	<u>0</u>	<u>as of date: March 31, 2026</u>

Exact title and class of the security:	<u>Series C Preferred</u>	
CUSIP (if applicable):	N/A	
Par or stated value:	<u>\$0.001</u>	
Total shares authorized:	<u>3,900,000</u>	<u>as of date: March 31, 2026</u>
Total shares outstanding (if applicable):	<u>2,675,000</u>	<u>as of date: March 31, 2026</u>
Total number of shareholders of record (if applicable):	<u>1</u>	<u>as of date: March 31, 2026</u>

Exact title and class of the security:	<u>Series D Convertible Preferred Stock</u>	
CUSIP (if applicable):	N/A	
Par or stated value:	<u>\$0.001</u>	
Total shares authorized:	<u>100,000</u>	<u>as of date: March 31, 2026</u>
Total shares outstanding (if applicable):	<u>100,000</u>	<u>as of date: March 31, 2026</u>
Total number of shareholders of record (if applicable):	<u>2</u>	<u>as of date: March 31, 2026</u>

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

One for one voting on all common stock, entitled to dividends as determined by the board of directors. No Pre-emptive rights.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

Series A Convertible Preferred Stock- Voting Rights- Shall be entitled to the number of votes as shall be equal to the aggregate number of shares of Common Stock into which the Series A shall be convertible. Liquidation – Holders shall be entitled to receive out of the assets of the corporation an amount equal to the Holder's pro rata share of the assets and funds of the corporation to be distributed. Conversion- Convertible into fully paid and non- assessable shares of Common Stock in aggregate equal to 20% of the post conversion number of shares of Common Stock issued and outstanding. Individual shares of Preferred Stock shall be convertible into that pro-rata number of common shares equal to .00001 X the aggregate number of shares issuable. There are no redemption rights.

Series B Preferred Stock – The holders of outstanding shares of Series B Preferred Stock shall be entitled, while shares of the Series B Preferred stock are outstanding, to cash dividends consisting in the aggregate of \$3,375,000 (the "**Special Dividend Amount**") subject to certain conditions as set forth in the certificate of designation. The holders of Series B Preferred shall also be entitled to cumulative dividends. Liquidation- The holders of Series B Preferred shall be entitled to receive, pro rata based on the number of shares of Series B Preferred Stock held, pari passu with the payment or distribution of assets of the Company to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the sum of (A) the Purchase Price plus an annualized internal rate of return of 8% for the period from the issuance date of the issued and outstanding Series B Preferred Stock to the date when all amounts under this section are in full, and (B) an amount equal to all declared but unpaid dividends for each outstanding share of Series B Preferred Stock proportionally adjusted for recapitalizations. Conversion- shall be convertible into fully paid and non- assessable shares of Common Stock as is determined by dividing the Purchase Price by the conversion price. The initial conversion price shall be \$0.0909, which implies that each share of Series B Preferred Stock is initially convertible into Common Stock on a 1- to- 100 basis. Voting Rights- Series B Preferred shall have the right to such number of votes for each share of common stock into which such share of Series B Preferred stock may then be converted pursuant to Section 5 of the Certificate of Designation equal to fifty-one percent (51%) of the outstanding common stock on an as-converted basis, only with respect to a proposal to amend the Certificate of Incorporation to increase the number of shares of capital stock authorized thereunder. In addition, the holders of Series B preferred shall have the right to

two (2) votes for each share of common stock into which such share of Series B Preferred Stock could then be converted. There are no redemption rights.

Series C Preferred- Dividends- Shall not be entitled to receive any dividends. Voting- Shall vote together with the common stock as a single class on a one hundred (100) votes per share of Series C Preferred basis. No Preemption rights. Redemption rights: The corporation shall have the right to redeem the shares of Series C Preferred at any time after the date of issuance at a per share price equal to the per share price paid for such shares. In addition, the holder of Series C Preferred may also require the corporation to redeem shares of Series C Preferred at any time after the date of issuance at per share price equal to the price paid by the holder for such shares. Any such redemption shall occur ten days after written notice of the redemption is provided. There are no liquidated rights.

Series D Convertible Preferred Stock- Voting- Shall be entitled to the number of votes as shall be equal to the aggregate number of shares of Common Stock into which the Series D shall be convertible. Liquidation- Upon Liquidation, the Holders shall be entitled to receive an amount equal to the Holder's pro rata share of the assets and funds of the corporation to be distributed. Conversion- The number of shares of common stock to which a Holder of Preferred Stock shall, in aggregate, equal 75% of the post conversion number of shares of Common Stock issued and outstanding. Individual shares of Series D preferred stock shall be convertible into that pro-rata number of common shares equal to .00001 x the aggregate number of shares issuable. There are no redemption rights

3. **Describe any other material rights of common or preferred stockholders.**

N/A

4. **Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.**

N/A

3) Issuance History

*The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.***

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes: (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> Date <u>12/31/2020</u> Common: 4,874,316,008 Preferred: <u>3,355,126</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
02/11/2021	Issuance	461,330,466	Common	<u>.004</u>	No	<u>Union Capital, LLC Yakov Borenstein</u>	Note conversion	Unrestricted	<u>4(a)1</u>
02/24/2021	Issuance	468,030,000	Common	<u>.0018</u>	No	<u>BB Winks LLC Craig Fisher</u>	Note conversion	Unrestricted	<u>4(a)1</u>
4/28/2021	Issuance	271,867,306	Common	<u>.0016</u>	Yes	<u>Union Capital, LLC Yakov Borenstein</u>	Note conversion	Unrestricted	<u>4(a)1</u>
06/01/2021	Issuance	460,000,000	Common	<u>.0016</u>	Yes	<u>Bruce Lewis</u>	Note Conversion	Unrestricted	<u>4(a)1</u>
6/22/21	Issuance	12,523,985	Common	<u>.0016</u>	Yes	<u>Gel Properties LLC Aryeh Goldstein</u>	Note Conversion	Unrestricted	<u>4(a)1</u>
6/23/21	Issuance	308,276,015	Common	<u>.0015</u>	Yes	<u>Gel Properties LLC Aryeh Goldstein</u>	Note Conversion	Unrestricted	<u>4(a)1</u>
6/22/21	Issuance	70,000,000	Common	<u>.0015</u>	Yes	<u>Gel Properties LLC Aryeh Goldstein</u>	Note Conversion	Unrestricted	<u>4(a)1</u>
6/22/21	Issuance	9,200,000	Common	<u>.0015</u>	Yes	<u>Gel Properties LLC Aryeh Goldstein</u>	Note Conversion	Unrestricted	<u>4(a)1</u>
9/23/21	Issuance	145,370,766	Common	<u>.002</u>	Yes	<u>Lance Quartieri</u>	Note Conversion	Unrestricted	<u>4(a)1</u>
9/20/21	Issuance	307,258,460	Common	<u>.002</u>	Yes	<u>Richard Grossfeld</u>	Pref A Conversion	Unrestricted	<u>4(a)1</u>
9/20/21	Cancellation	(22,151)	Pref A	<u>N/A</u>	N/A	<u>Richard Grossfeld</u>	Conversion to common	N/A	<u>N/A</u>
10/15/21	Cancellation	(46,052)	Pref B	<u>N/A</u>	N/A	<u>Jamie Safier</u>	Conversion to Pref A	N/A	<u>N/A</u>
10/15/21	Issuance	30,000	Pref A	<u>.002</u>	No	<u>Jamie Safier</u>	Conversion of Pref B	Unrestricted	<u>4(a)1</u>

10/26/21	Cancellation	(30,000)	Pref A	<u>N/A</u>	N/A	<u>Jamie Safier</u>	Conversion to common	N/A	<u>N/A</u>
10/26/21	Issuance	443,290,500	Common	<u>.002</u>	Yes	<u>Jamie Safier</u>	Conversion of Pref A	Unrestricted	<u>4(a)1</u>
1/13/2022	Issuance	150,035,000	Common	<u>.001</u>	Yes	<u>Walter Deal</u>	Conversion of debt	Unrestricted	<u>4(a)1</u>
5/25/2022	Issuance Cancellation	391,093,524 (24,500)	Common Pref A	<u>.002</u> <u>N/A</u>	Yes N/A	<u>David Lewis</u>	Conversion of Pref A	unrestricted	<u>4(a)1</u>
6/3/2022	Issuance Issuance	66,666 33,335	Pref D Pref A	<u>.002</u> <u>.002</u>	No No	<u>Dr. Jamalooddeen</u>	Share exchange	Restricted Restricted	<u>4(a)2</u>
6/3/2022	Issuance Issuance	33,333 16,666	Pref D Pref A	<u>.002</u> <u>.002</u>	No No	<u>Dylon DuPlooy</u>	Share exchange	Restricted Restricted	<u>4(a)2</u>
7/2/2023	Issuance Returned to treasury	418,629,601 (25,000)	Common Pref A	<u>.002</u> <u>N/A</u>	N/A	<u>Walter Deal</u>	Conversion of Pref A	unrestricted	<u>4(a)1</u>
Shares Outstanding on Date of This Report:									
<u>Ending Balance</u>									
<u>Ending Balance:</u>									
Date <u>3/31/2026</u>	Common: <u>8,791,221,631</u> Preferred: <u>3,387,423</u>								

Example: A company with a fiscal year end of December 31st 2024, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2023 through December 31, 2024 pursuant to the tabular format above.

Any additional material details, including footnotes to the table are below:

B. Convertible Debt

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

B. List any subsidiaries, parent company, or affiliated companies.

Plandai Biotechnology
Cannabis Biosciences, Inc.
RSAMMD Acquisitions LLC

C. Describe the issuers' principal products or services.

Through its prior acquisitions, Protect engages in the research, testing and development of highly bioavailable botanical products all-natural ingredients formulated for nutraceutical and pharmaceutical applications through the use of proprietary live plant extraction technology.

5) Issuer's Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The issuer utilizes space provided by its chairman at no cost. Location is 10 Hilldrop Dr. Newcastle, SA. 2940.

6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities. If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, 5% Control person)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
--	--	---	--	--	---

Steve Berman ¹	<u>Holder of more than 5% of a class of securities</u>	New York, NY	2,675,000	Series C Preferred	100%
Dr. A Jamalodeen	Chairman/President	<u>Newcastle, South Africa</u>	66,667 33,333 202,366,874	Pref D Pref A Common	67.7% 44.5% 2.3%
Dylon Du Plooy	CEO/Director	<u>Newcastle, South Africa</u>	33,333 16,667	Pref D Pref A	33.3% 22.2%

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

- 1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

No

- 2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person’s involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

No

- 3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

No

- 4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a “yes” answer to part 3 above; or

¹ Voting stock only, converts to 535 million votes equal to approx. 6% Preferred holder is not a control person or affiliate and has no conversion rights.

No

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

No

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

No

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

No

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com.

If any updates are needed to your public company profile, update your company profile.

Securities Counsel

Name: Jonathan Leinwand
Firm: Jonathan D. Leinwand, P.A.
Address 1: 18305 Biscayne Blvd, Suite 200
Address 2: Aventura, FL 33180
Phone: (954) 903-7856
Email: jonathan@jdlpa.com

Accountant or Auditor

Name: Michael Ussery, CPA
Firm: Kral Ussery, LLC
Address 1: 556 Silicon Drive, Suite 103
Address 2: Southlake, TX, 76092
Phone: 817-416-6842 ext.101
Email: MUssery@KralUssery.com

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

All other means of Investor Communication:

X (Twitter): _____
Discord: _____
LinkedIn: _____
Facebook: _____
[Other] _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: Marchello Beriy
Firm: Jonathan D. Leinwand, P.A.
Nature of Services: Assisted with preparation of disclosure statement
Address 1: 18305 Biscayne Blvd, Suite 200
Address 2:
Phone: (954) 903-7856
Email: mberiy@jdlpa.com

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: Marchello Beriy
Title: Attorney
Relationship to Issuer: Attorney

B. The following financial statements were prepared in accordance with:

- IFRS
 U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Michael Ussery

Title: CPA

Relationship to Issuer: Accountant

Describe the qualifications of the person or persons who prepared the financial statements:⁶ Mr. Ussery is a certified public accountant.

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be “machine readable”. Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Dylon Du Plooy certify that:

1. I have reviewed this Disclosure Statement for PROTEXT MOBILITY, INC (aka Protex Pharma, Inc.);
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

⁶ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

05/20/2026 [Date]

/S/ Dylan Du Plooy [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Dylan Du Plooy certify that:

1. I have reviewed this Disclosure Statement for PROTEXT MOBILITY, INC (aka Protex Pharma, Inc.);
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

05/20/2026 [Date]

/S/ Dylan Du Plooy [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Protext Mobility, Inc.
(aka Protext Pharma, Inc.)
OTCPK: TXTM
Financial Statements
March 31, 2026
(Unaudited)

PROTEXT MOBILITY, INC.
(aka Protex Pharma, Inc.)
Balance Sheets
(Unaudited)

	March 31,	December 31,
	2026	2025
ASSETS		
Cash	\$ -	\$ -
Inventory-Genus Cannabis Sativa Seeds	605,000,000	540,000,000
Inventory-Active Pharmaceutical Ingredients	6,298,000	6,298,000
Prepaid expenses	7,630	9,880
Total Current Assets	<u>611,305,630</u>	<u>546,307,880</u>
TOTAL ASSETS	<u>\$ 611,305,630</u>	<u>\$ 546,307,880</u>
LIABILITIES & EQUITY		
Current Liabilities		
Accrued Expenses	\$ -	\$ -
Accounts Payable	22,112	14,113
Related Party Line of Credit	159,240	151,934
Total Current Liabilities	<u>181,352</u>	<u>166,047</u>
Total Liabilities	181,352	166,047
Equity		
Common Stock, 10,000,000,000 shares par value \$0.00001 authorized, 8,791,221,631 issued and outstanding	87,912	87,912
Common Stock Issuable	-	-
Additional Paid-in Capital	614,065,451	549,065,451
Preferred Stock-Series A 100,000 par value \$0.001 shares authorized, 50,000 shares issued and outstanding	50	50
Preferred Stock-Series B 1,000,000 par value \$0.0001 shares authorized, 0 and 0 shares issued and outstanding	-	-
Preferred Stock - Series C 3,900,000 par value \$0.001 shares authorized, 2,675,000 issued and outstanding	2,675	2,675
Preferred Stock - Series D 100,000 par value \$0.001 shares authorized, 100,000 shares issued and outstanding, respectively	100	100
Retained Deficit	(3,031,910)	(3,014,355)
Total Equity	<u>611,124,278</u>	<u>546,141,833</u>
TOTAL LIABILITIES & EQUITY	<u>\$ 611,305,630</u>	<u>\$ 546,307,880</u>

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements

PROTEXT MOBILITY, INC.
(aka Protext Pharma, Inc.)
Statements of Operations
(Unaudited)

**For the three month period
ended March 31,**

	2026	2025
Expenses		
Professional Services	8,698	150
General and Admin	7,302	3,480
Total Expense	16,000	3,630
Net Operating Loss	(16,000)	(3,630)
Other Income (expense)		
Interest Expense	(1,555)	(1,099)
Total Other Income (Expense)	(1,555)	(1,099)
Net Income (Loss)	\$ (17,555)	\$ (4,729)

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements

PROTEXT MOBILITY, INC.

Statements of Equity

(Unaudited)

	Shares Outstanding	Common Stock	Series A Preferred	Series B Preferred	Series C Preferred	Series D Preferred	Paid In Capital	Stock Issuable	Retained Earnings	Total
Balance at December 31, 2024	8,791,221,631	\$ 87,912	\$ 50	\$ -	\$ 2,675	\$ 100	\$ 257,767,451	\$ -	\$ (3,524,546)	\$ 254,333,642
Net Loss for the period									(4,729)	(4,729)
Balance at March 31, 2025	\$ 8,791,221,631	\$ 87,912	\$ 50	\$ -	\$ 2,675	\$ 100	\$ 257,767,451	\$ -	\$ (3,529,275)	\$ 254,328,913
Balance at December 31, 2025	8,791,221,631	\$ 87,912	\$ 50	\$ -	\$ 2,675	\$ 100	\$ 549,062,451	\$ -	\$ (3,014,355)	\$ 546,141,833
Contribution of Seeds by shareholder							65,000,000			65,000,000
Net Loss for the period									(17,555)	(17,555)
Balance at March 31, 2026	\$ 8,791,221,631	\$ 87,912	\$ 50	\$ -	\$ 2,675	\$ 100	\$ 614,062,451	\$ -	\$ (3,031,910)	\$ 611,124,278

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements

PROTEXT MOBILITY, INC.
(aka Protext Pharma, Inc)
Statements of Cash Flows
(Unaudited)

	For the Three Ended March 31,	
	2026	2025
Cash Used in Operations:		
Net Income (loss)	\$ (17,555)	\$ (4,729)
Non-cash Adjustments to operating accounts		
Change in accrued expenses and prepaids	10,249	630
Net cash used in operating activities	<u>(7,306)</u>	<u>(4,099)</u>
Cash Provided from Financing Activities		
Related Party Line of Credit	7,306	4,099
Net Cash Provided by Financing Activities	<u>7,306</u>	<u>4,099</u>
Net Change in Cash Flow	-	-
Cash at beginning of period	-	-
Cash at end of period	<u>\$ -</u>	<u>\$ -</u>
Supplemental Cash Flow Information:		
Cash Paid for -		
Interest	\$ -	\$ -
Taxes	\$ -	\$ -
Conversion of Series A to Common	\$ -	\$ -
Shares issued on conversion of debt and interest		
Stock issued on acquisition	\$ -	\$ -
Contribution of Seeds	\$ -	\$ -

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

PROTEXT MOBILITY, INC.
(aka Protext Pharma, Inc.)
Notes to Consolidated Financial Statements
December 31, 2025

NOTE 1 - DESCRIPTION OF BUSINESS, OPERATIONAL UPDATE AND GOING CONCERN

Description of Business

ProText Mobility Inc. (the “Company”) was incorporated in the State of Delaware on September 5, 2001 under the name SearchHelp, Inc. and completed its initial public offering on July 23, 2003. During the fiscal year ended December 31, 2008, the Company acquired 100% of the stock of EchoMetrix, Inc, which then became a wholly owned subsidiary, and in May of 2009 the Company filed a Certificate of Ownership and Merger with the State of Delaware pursuant to which EchoMetrix was merged with and into the Company, and the Company's corporate name was changed to EchoMetrix, Inc. In December 2010, the Company filed a Certificate of Ownership and Merger with the state of Delaware pursuant to which the Company's then wholly owned subsidiary, ProText Mobility, Inc., was merged with and into the Company, and the Company's corporate name was changed to Protext Mobility, Inc.

On December 31, 2016, the Company acquired Plandaí Biotechnology South Africa (Pty) Ltd. (Plandaí), a South African company headquartered in the Mpumalanga province of South Africa through a share exchange agreement, and changed the corporate name to Protext Pharma, Inc. Plandaí was formed in 2014 and focuses on the development of pharmaceutical applications for botanical drugs and has the worldwide exclusive license to develop Phytofare® in botanical drug applications. Phytofare® is a highly bioavailable extract produced from live green tea leaves that has been clinically proven in double-blind human trials to have ten-times greater bioavailability over generic extract. The Company plans to commence human clinical trials to determine the effectiveness of using Phytofare® catechin complex in regulating insulin levels in Type II Diabetes patients. Under the terms of acquisition, the Company issued 100,000 shares of Series D Preferred Stock in exchange for all of the issued and outstanding shares of Plandaí. The Series D Preferred have the right to convert into 75% of the post-conversion issued and outstanding common stock of the Company. The Series D Preferred have voting rights equal to the number of shares issuable on conversion on all shareholder matters. On May 1, 2020, Plandaí Biotechnology, Inc., the entity from which Plandaí Biotechnology South Africa was acquired, agreed to return and cancel all Series D shares due to breach of contract.

As a result of the acquisition of Plandaí, the former shareholders of Plandaí became the control entity, having voting and conversion rights equal to 75%. Plandaí elected to become the successor issuer to the Company for accounting and reporting purposes. Accordingly, the accompanying financial statements represent the results of operations of Plandaí Biotechnology South Africa exclusive of those of ProText Mobility. The balance sheet contains the consolidated assets and liabilities of both entities for all periods presented while the retained deficit is that of Plandaí exclusively. The shares of common stock of ProText Mobility outstanding as of the acquisition date are shown as issued as of the acquisition date while the shares issued to acquire Plandaí are shown as outstanding for all periods presented.

On March 14, 2017, the Company acquired 100% of the capital stock of Cannabis Biosciences, Inc., in exchange for 50,000,000 shares of the Company's restricted common stock. Cannabis Biosciences is engaged in the development of a non-psychoactive, full-profile cannabis extract using the Phytofare® technology for pharmaceutical applications. The operations of Cannabis Biosciences from the date of the acquisition forward have been consolidated in these financial statements.

On June 3, 2022, the Company acquired 100% of the capital stock of RSAMMD Acquisition LLC, a Delaware corporation (“RSAMMDA”), in exchange for 100,000 shares of Series D Preferred Stock and 50,000 shares of Series A Preferred Stock (the “Acquisition Agreement”). The Series D Preferred have the right to convert into 75% of the post-conversion issued and outstanding common stock of the Company. The Series D Preferred have voting rights equal to the number of shares issuable on conversion on all shareholder matters. The Series A Preferred issued have conversion rights equal to 10% of the post-conversion issued and outstanding shares of common stock and voting rights equivalent to the total shares issuable on conversion. This transaction resulted in a change of control with the shareholders of RSAMMDA controlling over 85% of the total voting stock of the Company.

The sole shareholders of RSAMMDA were Mr. Dylon Du Plooy and Dr. Ahmed Jamalooden who also served as the chief financial officer and chief executive officers, respectively, of RSAMMDA. Both assumed similar roles at the Company. RSAMMDA had no operations or assets prior to the acquisition. The acquisition of RSAMMDA was accounted for as a capital transaction. The Company recorded the issuance of the Series D Preferred Stock and the Series A Preferred Stock at the par value with an equal amount recorded in APIC.

As a condition of the Acquisition Agreement, all accrued and unpaid expenses and loans, which primarily consisted of accrued and unpaid consulting fees to the Company's prior chief executive officer, were cancelled and forgiven. The cancelled obligations were approximately \$708,677.

RSAMMDA was formed on January 14, 2022 to facilitate a working relationship to commercialize the Company's proprietary live plant extraction system. Management is developing a sustainable business to leverage the same, including distribution.

Operational Update

Letter of Intent

In the fourth quarter of 2025, the Company entered into a non-binding Letter of Intent with TruLeaf South Africa to explore a potential strategic transaction. Discussions remain preliminary, and there can be no assurance that a transaction will be completed.

Financial Statements and Audit Status

The Company had previously completed International Financial Reporting Standards ("IFRS") audited financial statements for the years 2022 and 2023. The 2024 and 2025 IFRS audit are in progress. Management intends to utilize these audited financials to support potential future PCAOB- and SEC-compliant Form 10 filings. As an OTC-listed issuer, the Company is not required to provide PCAOB-level audits; IFRS continues to be the internationally recognized accounting framework used across most global exchanges.

Technical and Digital Infrastructure Progress

The Company continues to advance its technical and digital initiatives. An updated Investor Relations (IR) portal, hosted on WordPress, is scheduled for completion by the end of November. In parallel, development of a new corporate website is underway to improve information accessibility and enhance overall transparency for shareholders. The Company has begun voluntary EDGAR submissions, initially including Forms 4 and 8-K, to align future disclosures more closely with SEC reporting standards.

Advisory Board Update

The Company intends to announce its next advisory board member in the second or third quarter of 2026 and expects it to be a 20-year career diplomat. The previously appointed advisor — the current South African Ambassador to Chad — continues to provide valuable strategic insight, particularly with respect to global trade dynamics, BRICS initiatives, and the African Continental Free Trade Area (AfCFTA)

Currency Impact

The Company continues to benefit from a strengthening South African Rand relative to the U.S. dollar, with the exchange rate reaching R15.72 at January 28, 2026. This favorable movement positively impacts the Company's IFRS balance sheet under foreign exchange gains and is expected to continue contributing to improved financial positioning.

Going Concern

The Company's consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

The Company generated a net loss of \$17,555 for the period ended March 31, 2026 and net income of \$510,191 for the year ended December 31, 2025. The net income in 2025 was the result of a legal settlement to forgive an accrued liability with no cash flow impact.

As of March 31, 2026, the Company had stockholders' equity of \$611,124,278 and total liabilities of \$181,352. The Company had working capital of \$ 611,124,278. The Company has no cash and its primary assets are comprised of Genus Cannabis Sativa seeds and Active Pharmaceutical Ingredients donated by the Company's major shareholder. The Company has recorded no sales during any of the periods presented.

These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for the twelve months following the issuance of its financial statements for the three months ended March 31, 2026. The Company's ability to continue as a going concern is dependent upon its ability to utilize the resources in place to generate future profitable operations and to obtain the necessary financing to meet its debt obligations and repay its liabilities arising from business operations when they come due. Management believes that with the recent acquisition of RSAMMDA and the change in management, the Company will be able to leverage the expertise and relationships of Management to develop its proprietary live plant extraction technology as well as its distribution network.

Although the Company believes that it will be successful, these conditions continue to raise substantial doubt regarding the Company's ability to continue as a going concern.

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States.

Use of Estimates

The preparation of financial statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses in the reporting period. We regularly evaluate our estimates and assumptions related to the useful life and recoverability of long-lived assets, stock-based compensation and deferred income tax asset valuation allowances. We base our estimates and assumptions on current facts, historical experience and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by us may differ materially and adversely from our estimates. To the extent there are material differences between our estimates and the actual results, our future results of operations will be affected.

Cash and Cash Equivalents

The Company considers all highly liquid instruments with original maturities of three months or less when acquired, to be cash equivalents.

Income Taxes

The Company accounts for income taxes under the provisions issued by the FASB which requires recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The Company computes tax asset benefits for net operating losses carried forward. The potential benefit of net operating losses has not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.

Fair Value of Financial Instruments

Pursuant to ASC No. 820, “Fair Value Measurements and Disclosures”, the Company is required to estimate the fair value of all financial instruments included on its balance sheet as of December 31, 2025 and December 31, 2024. The Company does not have any financial instruments as of those dates. The Company considers the carrying value of such amounts in the financial statements to approximate their fair value due to the short-term nature of these financial instruments.

The Company adopted ASC No. 820-10 (ASC 820-10), Fair Value Measurements. ASC 820-10 relates to financial assets and financial liabilities. ASC 820-10 defines fair value, establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America (GAAP), and expands disclosures about fair value measurements. The provisions of this standard apply to other accounting pronouncements that require or permit fair value measurements and are to be applied prospectively with limited exceptions.

ASC 820-10 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. This standard is now the single source in GAAP for the definition of fair value, except for the fair value of leased property as defined in SFAS 13. ASC 820-10 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions, about market participant assumptions, that are developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820-10 are described below:

- Level 1 Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
- Level 2 Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
- Level 3 Inputs that are both significant to the fair value measurement and unobservable. These inputs rely on management's own assumptions about the assumptions that market participants would use in pricing the asset or liability. (The unobservable inputs are developed based on the best information available in the circumstances and may include the Company's own data.)

There are no assets and liabilities measured at fair value on a non-recurring basis as of March 31, 2026 and December 31, 2025.

Inventory-Genus Cannabis Sativa Seeds

Inventory consists of 1,900,000,000 genus cannabis sativa seeds (the “Seeds”) and is recorded at the lower of estimated historical cost or net realizable value. The Seeds were contributed to the Company by Company’s President and Chairman of the Board. Historical cost was determined based on the historical cost of the Seeds to the Company’s President and Chairman of the Board which included the cost of acquisition, growing, cultivating and harvesting the Seeds. (See Note 4 -Related Party – Inventory- Genus Cannabis Sativa Seeds).

Inventory- Active Pharmaceutical Ingredients

Inventory also consists of 125,959,995 mg of Active Pharmaceutical Ingredients (“APIs”) and is recorded at the lower of estimated historical cost or net realizable value. The APIs were contributed to the Company by True Leaf Holdings (“TruLeaf”) with an estimated fair market value of \$10,710,000. TruLeaf is wholly owned and controlled by Dr. RS

Hurley, who is the spouse of the President and Chairman of the Board of Directors of the Company. Historical cost was determined based on the historical cost of the APIs to TruLeaf (See Note 4 -Related Party – Active Pharmaceutical Ingredients)

NOTE 3 - EQUITY

Common Stock

The Company has authorized 10 billion shares of common stock, par value \$0.00001, of which 8,791,221,631 shares were issued and outstanding as of March 31, 2026 and December 31, 2025.

Series A Preferred

The Company has 100,000 shares of Series A Preferred stock, par value \$0.001, authorized of which 50,000 shares were issued and outstanding on March 31, 2026 and December 31, 2025. The Series A Preferred has conversion rights equal to 10% of the post-conversion issued and outstanding shares of common stock and voting rights equivalent to the total shares issuable on conversion.

Series B Preferred

As of March 31, 2026 and December 31, 2025, there were no shares of Series B Preferred issued and outstanding. The Series B Preferred has voting rights equal to two votes per share on all shareholder matters and has a preference on dividend payments.

Series C Preferred

The Company has authorized 3,900,000 shares of Series C Preferred stock, par value \$0.001. As of March 31, 2026 and December 31, 2025 there were 2,675,000 Series C shares outstanding. The Series C have voting rights equal to 200 votes per share on all shareholder matters.

Series D Preferred

On June 3, 2022, the Company issued 100,000 shares of Series D Preferred stock as partial consideration for the Acquisition Agreement. The Series D Preferred stock has conversion rights equal to 75% of the post-conversion common stock and voting rights equivalent to the number of shares issuable on conversion.

NOTE 4 - RELATED PARTY TRANSACTIONS

Borrowings and related party stock purchase program

During 2022, Company's President and Chairman of the Board paid certain bills including registration fees and legal fees on behalf of the Company. Such payments aggregated approximately \$8,644. On December 31, 2022, Company's President and Chairman of the Board offered and the board of directors agreed to extend the Company a line of credit in the amount of \$100,000 with interest of 4% per annum. The \$8,644 payable to Company's President and Chairman of the Board was converted into the line of credit. During the three month periods ended March 31, 2026 and 2025, the Company's President and Chairman of the Board made payments on behalf of the Company in the amount of \$5,750 and \$2,999 respectively. The Balance of the line of credit as of March 31, 2026 and December 31, 2025 was \$159,240 and \$151,934, respectively. During the three month periods ended March 31, 2026 and 2025, the Company recognized \$1,555 and \$1,099 in interest expense relating to the line of credit.

The Company's CEO, and the Company's President and Chairman of the Board each earn a salary of \$1.00 per year.

Dr. A Jamalooden (chairman and president) has implemented, with consent of additional shareholders, an open ended, discretionary, stock purchase program. Through March 31, 2026, Dr. A Jamalooden purchased a total of 775,655,004 shares from other shareholders under the program. The purchase had no impact on the Company's financial statements.

Inventory- Genus Cannabis Sativa Seeds

On December 15, 2022, the Company's President and Chairman of the Board contributed approximately 15,000,000 Genus Cannabis Sativa Seeds (the "Seeds") to the Company as an equity contribution (the "Contribution"). The Contribution was recorded as Genus Cannabis Sativa Seed inventory at historical cost to the Company's President and Chairman of the Board of approximately \$1 per seed (R17.0301 per seed at December 15, 2022).

During 2024, the Company's President and Chairman of the Board contributed a total of 240,000,000 Seeds to the Company as equity contributions. All contributions were recorded at historical cost to the Company's President and Chairman of the Board of approximately \$1 per seed. (R18.3996 per seed at May 15, 2024).

In October, 2023, the Company entered into a seed multiplication agreement with a related party ("Grower") to plant, germinate and process the Company's seed inventory. In exchange, the upon harvesting, the Grower will deliver new seeds to the Company in the amount of approximately four times the number of seeds delivered under the program. The agreement is subject to customary representations and warranties, including specifications of the new seed quality.

On April 1, 2024, and on October 1, 2024 Seeds were delivered to Grower to plant and germinate. During the planting cycle rotation, the seeds were successfully germinated, harvested and processed. On June 28, 2024, and December 30, 2024, the Grower delivered to the Company the agreed upon new Seeds. No consideration was exchanged in the multiplication agreement and the 460,000,000 seeds received were recorded at the historical cost of the original contribution.

On April 6, 2025, the Company delivered 600,000,000 seeds to Grower to plant and germinate. The Company considers seeds planted under the germination program to be Company seed inventory. On June 26, 2025, the Grower returned the original 600,000,000 Seed inventory plus 400,000,000 for a total of 1 billion seeds in inventory.

On June 30, 2025, the Company's President and Chairman of the Board contributed an additional 250,000,000 Seeds to the Company as an equity contribution. The contribution was recorded as Genus Cannabis Sativa Seed inventory at historical cost to the Company's President and Chairman of the Board of approximately \$1 per seed.

In October, 2025, the Company delivered 1.25 billion seeds to Grower to plant and germinate. The Company considers seeds planted under the germination program to be Company seed inventory. In December, 2025, the Grower returned the original 1.25 billion Seed inventory plus 250,000,000 for a total of 1.5 billion seeds in inventory.

In December 2025, the Company's President and Chairman of the Board contributed an additional 35,000,000 Seeds to the Company as an equity contribution. The contribution was recorded as Genus Cannabis Sativa Seed inventory at historical cost to the Company's President and Chairman of the Board of approximately \$1 per seed.

In January, 2026, the Company delivered 1.535 billion seeds to Grower to plant and germinate. The Company considers seeds planted under the germination program to be Company seed inventory. In March, 2026, the Grower returned the original 1.535 billion Seed inventory plus 300,000,000 for a total of 1.835 billion seeds in inventory.

In March 2026, the Company's President and Chairman of the Board contributed an additional 65,000,000 Seeds to the Company as an equity contribution. The contribution was recorded as Genus Cannabis Sativa Seed inventory at historical cost to the Company's President and Chairman of the Board of approximately \$1 per seed.

A roll forward of the seed inventory contributions and germination programs for the three month period ended March 31, 2026 and year ended December 31, 2025 is as follows:

Date	Description	Number of Seeds	Cost of Seeds (Equity contribution)
Seed inventory - December 31, 2024		600,000,000	\$255,000,000
<u>2025 equity contributions</u>			
6/30/2025	Equity Contribution	250,000,000	\$250,000,000
12/1/2025	Equity Contribution	35,000,000	\$35,000,000
	Total 2025 Contributions	285,000,000	\$285,000,000
<u>2025 Germination program</u>			
4/6/2025	Seeds delivered under germination program	(600,000,000)	(\$255,000,000)
6/26/2025	Seeds Returned	1,000,000,000	\$255,000,000
10/1/2025	Seeds delivered under germination program	(1,250,000,000)	(\$505,000,000)
12/30/2025	Seeds Returned	1,500,000,000	\$505,000,000
	Increase due to Seed Germination	650,000,000	\$ -
Seed inventory - December 31, 2025		1,535,000,000	\$540,000,000
<u>Three month peiorod ended March 31, 2026 equity contributions</u>			
3/31/2026	Equity Contribution	65,000,000	\$65,000,000
	Total Contributions for the period	65,000,000	\$65,000,000
<u>Three month peiorod ended March 31, 2026 Seed Germination Program</u>			
1/1/2026	Seeds delivered under germination program	(1,535,000,000)	(\$540,000,000)
3/30/2026	Seeds Returned	1,835,000,000	\$540,000,000
	Increase due to Seed Germination	300,000,000	\$ -
Seed inventory - March 31, 2026		1,900,000,000	\$605,000,000

The Company estimates the fair value of the seeds is substantially in excess of the recorded value of \$605,000,000. The spot price for similar seeds had a retail market price in the range of 15-25 euro per seed, excluding, but not limited to shipping, customs duty (if applicable), VAT, clearing agent fees, in-land haulage and other variable costs.

As of March 31, 2026, the company has 1,900,000,000 seeds in inventory.

Supply Agreement

As part of the Company's general business, it plans to fulfill orders and ship products to end customers around the world, including biomass derived from hemp, raw or processed CBD, and/or finished health and wellness products containing CBD (derived from Genus Cannabis Sativa). The end products are anticipated to be shipped as partial shipments (LCL) to the end customer in compliance with the rules and regulations of each jurisdiction involved by the responsible parties. Such that the Company can fulfill orders, the Company entered into a Supply Agreement with its President and Chairman of the Board in his capacity as an independent fourth generation farmer who controls, among other things, a 5,000 hectare farm in the jurisdiction of New Castle, South Africa. The Company's President and Chairman of the Board in his individual capacity as an independent farmer controls certain permits related to activities such as cultivation, import/export of various agricultural products including but not limited to genus cannabis sativa. The Company does not plant, own or control any farm, and has no permit.

The Company's President and Chairman of the Board, in his capacity as an independent farmer and a team, managed by the Company's CEO- Dylan Du Plooy, in his individual capacity, are responsible for planting hemp crops derived from Genus Cannabis Sativa seeds at a farm controlled by the Company's President and Chairman of the Board. In the future, the Company's President and Chairman of the Board may provide the Company with access to, and/or the Company may receive benefit from, permits controlled by the Chairman. There are no guarantees that this will occur. Furthermore, the Company does not need such access, specifically to permits held by its President and Chairman of the Board in his individual capacity as a private citizen and independent farmer within jurisdiction of South Africa, to carry out its business endeavors such as fulfilling and shipping product to end customers.

Inventory -Active Pharmaceutical Ingredients

On September 17, 2025, True Leaf Holdings ("TruLeaf") made a non-cash contribution to the Company consisting of 125,959,995 mg of APIs with an estimated fair market value of \$10,710,000. TruLeaf is wholly owned and controlled by Dr RS Hurley (Dr. H), who is the spouse of Company's President and Chairman of the Board. Accordingly, this transaction was recorded as an equity contribution at TruLeaf's historical cost of approximately \$6,298,000.

The contributed APIs were provided pursuant to a non-binding Letter of Intent designed to support the Company's medical, nutraceutical, and wellness research and development initiatives. The Company evaluated the substance of the transaction and determined that the contribution was made without preferential terms, did not involve any cash consideration, and was completed in the normal course of the parties' independent commercial operations.

Upon receipt, the APIs were recognized at their estimated fair market value as an increase in inventory (or R&D materials) with a corresponding recognition of non-cash contribution income in accordance with IFRS/GAAP. Management believes the valuation reflects an orderly market price for comparable pharmaceutical-grade materials at the measurement date.

NOTE 5 - STRATEGIC TOKENIZATION INITIATIVE AND PILOT PROGRAM

The Company's President and Chief Executive Officer in his personal capacity and through Leeds Investments and its assigns, has entered into a pilot-program Letter of Intent with ABSA Bank in South Africa. This initiative is in development and represents one of the first pilot programs of its kind within the region.

The contemplated framework includes real-world asset tokenization, the creation of Stablecoins, and associated custodial walleting solutions. These digital assets are intended to serve as collateral within the pilot program, with the potential to attract fixed-return investment products.

The proposed model integrates API connectivity, token issuance, liquidity pathways, and revenue-recognition mechanics. It is anticipated that the program may also encompass additional asset classes, including carbon credits.

While conducted outside the Company, the Company's President and Chairman of the Board, and management believes that expertise gained through this initiative could be strategically beneficial to the Company. In particular, it may inform future opportunities for the tokenization of certain real-world assets held or developed by TXTM — such as its rare, stabilized, high-value Cannabis sativa seed genetics — subject to applicable regulatory, technical, and commercial considerations.

ABSA Bank incorporates Ripple/XRP-based settlement technologies in certain systems, and the initiative may explore compatible digital-asset infrastructure. Splendor Labs' existing engagement with the African Union may also offer complementary strategic alignment with broader regional initiatives, including those associated with the African Continental Free Trade Area (AfCFTA).

NOTE 6 - SUBSEQUENT EVENTS

The Company reviewed transactions through May 20, 2026 and there were no material events.

Voluntary SEC Filing Program

The Company is a former SEC reporting company that currently has no obligation to file periodic or current reports under Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Company maintains its disclosure obligations through the OTC Markets Group's OTC Disclosure & News Service, under which this Annual Report is being filed.

In addition to its OTC Markets disclosures, the Company has voluntarily filed multiple Current Reports on Form 8-K on the SEC's EDGAR system pursuant to Item 8.01 of Form 8-K. These voluntary filings were made to introduce into the SEC's public record press releases and corporate disclosures that were previously or concurrently disseminated through the OTC Disclosure & News Service and other recognized news distribution channels. The Company intends to continue filing voluntary Form 8-K reports and such other supplementary documents as the Company deems appropriate on the EDGAR system on a going-forward basis.

This voluntary filing program is part of the Company's ongoing commitment to enhance transparency, strengthen its public disclosure practices, and prepare for a potential uplisting. All filings made under this program are and shall remain voluntary. The adoption and continuation of this program does not create, and shall not be construed to create, any obligation on the part of the Company to file current reports, periodic reports, or any other documents under Section 13 or 15(d) of the Exchange Act beyond what may otherwise be required by applicable law. The Company reserves the right to modify, suspend, or discontinue this voluntary filing program at any time and without prior notice.

Information filed on EDGAR pursuant to this program, including exhibits thereto, is deemed "filed" for purposes of Section 18 of the Exchange Act and shall be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent expressly superseded by information contained in any subsequent filing.